Cambridge hybrid closed‐loop use in very young children with type 1 diabetes: Parental expectancies during long‐term home use
Authors' conclusion
Prolonged HCL use supports sustained glycaemic benefits while parental positive expectancies regarding AID increase over time.
Study context
- Population
- Parents of young children aged 1–7 with T1D using CamAPS FX hybrid closed-loop (HCL)parents of children
- Participants
- 64 parents
- Comparison
- Parental expectancies and HbA1c at baseline vs HCL clinical trial phase vs after 18-month home-use extension
- Primary endpoint
- Parental expectancies regarding automated insulin delivery (AID) (INSPIRE questionnaire)
Methodological details18-month HCL extension phase, linear mixed models
- 18-month HCL extension phase
- Linear mixed models
Primary result
As reported in the abstract
Parental expectancies (INSPIRE)
d
0.05
P = 0.629
Clinical trial · did not change
d
1.14
P < 0.001
18-month extension · increased markedly
Baseline
44.78
± 34.70
Clinical trial
42.10
± 38.11
18-month extension
89.83
± 9.35
Further findings
HbA1c — Clinical trial vs Baseline
P < 0.001
% Baseline 7.3% · Clinical trial 6.8% · 18-month extension 6.8%
| Outcome | P value |
|---|---|
| HbA1c18-month extension vs Baseline · benefits sustained | P = 0.45 |
Original publication
Cambridge hybrid closed‐loop use in very young children with type 1 diabetes: Parental expectancies during long‐term home use. Diabet Med. Published 1 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →